Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-1.49%||176.12||0.7%||$1154.91m|
|LLY||Eli Lilly & Co.||-0.17%||368.68||1.1%||$1075.50m|
|MRK||Merck & Co., Inc.||-0.98%||108.93||0.7%||$992.38m|
|BMY||Bristol-Myers Squibb Co.||-0.98%||79.91||1.1%||$741.36m|
|HZNP||Horizon Therapeutics Plc||-1.66%||96.85||5.4%||$295.13m|
|IDXX||IDEXX Laboratories, Inc.||-1.64%||415.39||3.9%||$191.92m|
|ALNY||Alnylam Pharmaceuticals, Inc.||-2.90%||219.64||8.0%||$156.22m|
|NVO||Novo Nordisk A/S||-1.03%||125.77||0.1%||$154.68m|
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. It focuses on developing and commercializing the MyMD-1 and SUPERA-CBD therapeutic platforms. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune diseases. Supera-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.